Xenon Pharmaceuticals Prices $650M Public Offering
VANCOUVER, British Columbia & BOSTON — March 10, 2026 Global biotechnology company Xenon Pharmaceuticals Inc. has announced the pricing...
Alzheimer’s Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy cGxP Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP GMP compliance Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
VANCOUVER, British Columbia & BOSTON — March 10, 2026 Global biotechnology company Xenon Pharmaceuticals Inc. has announced the pricing...
BASEL, Switzerland – February 27, 2026 Novartis AG has successfully completed its acquisition of Avidity Biosciences, Inc., strengthening its...
North Chicago, Ill., September 26, 2025 – AbbVie (NYSE: ABBV) announced the submission of a New Drug Application (NDA)...
